FDA Approval: MARIPOSA, First-Line Amivantamab plus Lazertinib for EGFR NSCLC

On August 19th, the Food and Drug Administration approved lazertinib in combination with amivantamab for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations. In this episode of Lung Cancer Considered, host Dr. Narjust Florez talks with Dr. Julia Rotow from Dana-Faber Cancer Institute about this therapy and the MARIPOSA trial, which evaluated the use of lazertinib in combination with amivantamab.